Genomictree Inc. (KOSDAQ:228760)
South Korea flag South Korea · Delayed Price · Currency is KRW
11,180
-110 (-0.97%)
Sep 1, 2026, 3:30 PM KST

Genomictree Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
2,9463,7602,3623,41829,8665,140
Revenue Growth
-17.13%59.17%-30.89%-88.55%481.09%314.87%
Gross Profit
-164.4699-745.56-301.6224,9742,499
Operating Income
-11,738-11,298-15,313-17,3032,405-9,855
Net Income
-9,027-8,986-10,242-8,756-6,631-11,425
Earnings Per Share
-373.16-374.27-429.00-448.80-316.00-553.38
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
79,18177,36696,08093,146114,605130,542
Total Debt
43.982,3682,0791,83529,18038,444
Net Cash (Debt)
79,13774,99894,00191,31285,42592,098
Net Cash Growth
-5.79%-20.21%2.94%6.89%-7.25%0.57%
Net Cash Per Share
3271.483123.843937.193444.884069.684461.03

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-10,547-10,193-13,633-10,8814,286-7,631
Capital Expenditures
-1,860-2,726-2,484-239.08-1,762-10,963
Free Cash Flow
-12,407-12,919-16,118-11,1202,523-18,593
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-5.58%18.59%-31.56%-8.82%83.62%48.62%
Operating Margin
-398.40%-300.47%-648.24%-506.25%8.05%-191.75%
Pretax Margin
-311.63%-242.38%-439.79%-278.04%-12.37%-222.27%
Profit Margin
-306.37%-238.98%-433.57%-256.17%-22.20%-222.28%
FCF Margin
-421.10%-343.58%-682.29%-325.32%8.45%-361.76%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
----71.93-
PS Ratio
93.98175.37207.68142.436.0852.60